Integrating and Interpreting Findings from the Latest Treatment as Prevention Trials

Curr HIV/AIDS Rep. 2020 Jun;17(3):249-258. doi: 10.1007/s11904-020-00492-4.

Abstract

Purpose of review: In 2018-2019, studies were published assessing the effectiveness of reducing HIV incidence by expanding HIV testing, linkage to HIV treatment, and assistance to persons living with HIV to adhere to their medications (the "90-90-90" strategy). These tests of "treatment as prevention" (TasP) had complex results.

Recent findings: The TasP/ANRS 12249 study in South Africa, the SEARCH study in Kenya and Uganda, and one comparison (arms A to C) of the HPTN 071 (PopART) study in South Africa and Zambia did not demonstrate a community impact on HIV incidence. In contrast, the Botswana Ya Tsie study and the second comparison (arms B to C) of PopART indicated significant ≈ 30% reductions in HIV incidence in the intervention communities where TasP was expanded. We discuss the results of these trials and outline future research and challenges. These include the efficient expansion of widespread HIV testing, better linkage to care, and viral suppression among all persons living with HIV. A top implementation science priority for the next decade is to determine what strategies to use in specific local contexts.

Keywords: 90-90-90 targets; HIV; HIV care continuum; Implementation science; Sub-Saharan Africa; Treatment as prevention.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Anti-Retroviral Agents / therapeutic use*
  • Clinical Trials as Topic
  • Counseling
  • Female
  • HIV Infections / diagnosis
  • HIV Infections / drug therapy*
  • HIV Infections / epidemiology
  • HIV Infections / prevention & control*
  • Humans
  • Incidence
  • Kenya / epidemiology
  • Male
  • Mass Screening / methods*
  • South Africa / epidemiology
  • Uganda / epidemiology
  • Zambia / epidemiology

Substances

  • Anti-Retroviral Agents